Up to 1.8% of youth identify as transgender; many will be treated with a gonadotropin-releasing hormone agonist (GnRHa). The impact of GnRHa on insulin sensitivity and body composition in transgender youth is understudied. We aimed to evaluate differences in insulin sensitivity and body composition in transgender youth on GnRHa therapy compared with cisgender youth.
Methods:
Transgender participants were matched to cisgender participants on age, body mass index, and sex assigned at birth. Transgender males (n=9, ages 10.1–16.0 years) on GnRHa (mean±standard deviation duration of exposure: 20.9±19.8 months) were compared with cisgender females (n=14, ages 10.6–16.2). Transgender females (n=8, ages 12.6–16.1) on GnRHa (11.3±7 months) were compared with cisgender males (n=17, ages 12.5–15.5). Differences in insulin sensitivity (1/[fasting insulin], homeostatic model of insulin resistance [HOMA-IR]), glycemia (hemoglobin A1C [HbA1c], fasting glucose), and body composition (dual-energy X-ray absorptiometry) were evaluated using a mixed linear regression model.
Results:
Transgender males had lower 1/fasting insulin and higher HOMA-IR (p=0.031, p=0.01, respectively), fasting glucose (89±4 vs. 79±13 mg/dL, p=0.012), HbA1c (5.4±0.2 vs. 5.2±0.2%, p=0.039), and percent body fat (36±7 vs. 32±5%, p=0.042) than matched cisgender females. Transgender females had lower 1/fasting insulin and higher HOMA-IR (p=0.028, p=0.035), HbA1c (5.4±0.1% vs. 5.1±0.2%, p=0.007), percent body fat (31±9 vs. 24±10%, p=0.002), and lower percent lean mass (66±8 vs. 74±10%, p<0.001) than matched cisgender males.
Conclusion:
Transgender youth on a GnRHa have lower estimated insulin sensitivity and higher glycemic markers and body fat than cisgender controls with similar characteristics. Longitudinal studies are needed to understand the significance of these changes. Clinical Trial.gov ID: NCT02550431.
Get full access to this article
View all access options for this article.
References
1.
HermanJL, FloresAR, BrownTNT, et al.Age of Individuals Who Identify As Transgender in the United States. Los Angeles, CA: The Williams Institute, 2017.
2.
JohnsMM, LowryR, AndrzejewskiJ, et al.Transgender identity and experiences of violence victimization, substance use, suicide risk, and sexual risk behaviors among high school students—19 states and large urban school districts, 2017. MMWR Morb Mortal Wkly Rep. 2019; 68:67–71.
3.
HembreeWC, Cohen-KettenisPT, GoorenL, et al.Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017; 102:3869–3903.
4.
SkordisN, ButlerG, de VriesMC, et al.ESPE and PES international survey of centers and clinicians delivering specialist care for children and adolescents with gender dysphoria. Horm Res Paediatr. 2018; 90:326–331.
5.
de VriesALC, McGuireJK, SteensmaTD, et al.Young adult psychological outcome after puberty suppression and gender reassignment. Pediatrics. 2014; 134:696–704.
6.
de VriesALC, SteensmaTD, DoreleijersTAH, Cohen-KettenisPT. Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. J Sex Med. 2011; 8:2276–2283.
7.
OlsonKR, DurwoodL, DeMeulesM, McLaughlinKA. Mental health of transgender children who are supported in their identities. Pediatrics. 2016; 137:e20153223.
8.
RaffertyJ. Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents. Pediatrics. 2018; 142:e20182162.
9.
SchagenSE, Cohen-KettenisPT, Delemarre-van de WaalHA, HannemaSE. Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents. J Sex Med. 2016; 13:1125–1132.
10.
KlaverM, de MutsertR, WiepjesCM, et al.Early hormonal treatment affects body composition and body shape in young transgender adolescents. J Sex Med. 2018; 15:251–260.
11.
Loomba-AlbrechtLA, StyneDM. Effect of puberty on body composition. Curr Opin Endocrinol Diabetes Obes. 2009; 16:10–15.
12.
KeatingNL, O'MalleyAJ, FreedlandSJ, SmithMR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010; 102:39–46.
13.
NokoffNJ, ScarbroSL, MoreauKL, et al.Body composition and markers of cardiometabolic health in transgender youth compared to cisgender youth. J Clin Endocrinol Metab. 2019; 105:e704–e714.
14.
BjornstadP, TruongU, PyleL, et al.Youth with type 1 diabetes have worse strain and less pronounced sex differences in early echocardiographic markers of diabetic cardiomyopathy compared to their normoglycemic peers: a RESistance to InSulin in Type 1 ANd Type 2 diabetes (RESISTANT) study. J Diabetes Complications. 2016; 30:1103–1110.
15.
NokoffN, ThurstonJ, HilkinA, et al.Sex differences in effects of obesity on reproductive hormones and glucose metabolism in early puberty. J Clin Endocrinol Metab. 2019; 104:4390–4397.
16.
MarshallWA, TannerJM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969; 44:291–303.
17.
MarshallWA, TannerJM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970; 45:13–23.
18.
KuczmarskiRJ, OgdenCL, GuoSS, et al.2000. CDC growth charts for the United States: methods and development. Vital Health Stat, 11. 2002:1–190.
19.
HarrisPA, TaylorR, ThielkeR, et al.Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009; 42:377–381.
20.
GeorgeL, BachaF, LeeS, et al.Surrogate estimates of insulin sensitivity in obese youth along the spectrum of glucose tolerance from normal to prediabetes to diabetes. J Clin Endocrinol Metab. 2011; 96:2136–2145.
21.
MatthewsDR, HoskerJP, RudenskiAS, et al.Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412–419.
22.
FriedewaldWT, LevyRI, FredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499–502.
23.
Mauvais-JarvisF. Gender differences in glucose homeostasis and diabetes. Physiol Behav. 2018; 187:20–23.
24.
ChaoJ, RubinowKB, KratzM, et al.Short-term estrogen withdrawal increases adiposity in healthy men. J Clin Endocrinol Metab. 2016; 101:3724–3731.
25.
KeatingNL, O'MalleyAJ, SmithMR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24:4448–4456.
26.
WidenE, SilventoinenK, SovioU, et al.Pubertal timing and growth influences cardiometabolic risk factors in adult males and females. Diabetes Care. 2012; 35:850–856.
27.
MoranA, JacobsDR, SteinbergerJ, et al.Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes. 1999; 48:2039–2044.
28.
CopelandKC, ZeitlerP, GeffnerM, et al.Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011; 96:159–167.
29.
DabeleaD, Mayer-DavisEJ, SaydahS, et al.Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014; 311:1778–1786.
30.
Centers for Disease Control and Prevention. A Report of the Surgeon General Physical Activity and Health Adolescents and Young Adults. Atlanta, GA: Department of Health and Human Services, 1996.
31.
BootAM, De Muinck Keizer-SchramaS, PolsHA, et al.Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. J Clin Endocrinol Metab. 1998; 83:370–373.
32.
AlessandriSB, Pereira FdeA, VillelaRA, et al.Bone mineral density and body composition in girls with idiopathic central precocious puberty before and after treatment with a gonadotropin-releasing hormone agonist. Clinics (Sao Paulo). 2012; 67:591–596.
33.
ArcariAJ, FreireAV, EscobarME, et al.One-year treatment with gonadotropin-releasing hormone analogues does not affect body mass index, insulin sensitivity or lipid profile in girls with central precocious puberty. J Pediatr Endocrinol Metab. 2019; 32:181–186.
34.
ParkJ, KimJH. Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2017; 22:27–35.
35.
MarakaS, Singh OspinaN, Rodriguez-GutierrezR, et al.Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2017; 102:3914–3923.
36.
RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care. 2014; 37:780–788.
37.
ChanCL, PyleL, NewnesL, et al.Continuous glucose monitoring and its relationship to hemoglobin A1c and oral glucose tolerance testing in obese and prediabetic youth. J Clin Endocrinol Metab. 2015; 100:902–910.
38.
ParkC, GuallarE, LintonJA, et al.Fasting glucose level and the risk of incident atherosclerotic cardiovascular diseases. Diabetes Care. 2013; 36:1988–1993.
39.
NotaNM, WiepjesCM, de BlokCJM, et al.Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy. Circulation. 2019; 139:1461–1462.
